Comparative effectiveness and integrated safety of goserelin sustained-release microspheres versus implants in prostate cancer: a patient-based real-world study and systematic review with meta-analysis - Takeaways - MDSpire

Comparative effectiveness and integrated safety of goserelin sustained-release microspheres versus implants in prostate cancer: a patient-based real-world study and systematic review with meta-analysis

  • By

  • Jie Zhao

  • Qiang Zhao

  • Xiaohong Liu

  • Kun Hou

  • Yuan Chen

  • Hua Lan

  • Yaodong Ping

  • June 17, 2026

  • 0 min

Share

  • 1

    The study compared goserelin sustained-release microspheres and implants for androgen deprivation therapy in prostate cancer patients.

  • 2

    Eighty-seven patients were included, with 44 receiving microspheres and 43 receiving implants over a 12-week observation period.

  • 3

    At day 85, total prostate-specific antigen response rates were 86.4% for microspheres and 93.0% for implants, meeting non-inferiority criteria.

  • 4

    The systematic review included three studies with 665 patients, showing a pooled incidence of any-grade adverse events at 59.2%.

  • 5

    Goserelin microspheres demonstrated comparable effectiveness and a manageable safety profile, suggesting their viability as an ADT option.

Original Source(s)

Comparative effectiveness and integrated safety of goserelin sustained-release microspheres versus implants in prostate cancer: a patient-based real-world study and systematic review with meta-analysis

  • by Jie Zhao, Qiang Zhao, Xiaohong Liu, Kun Hou, Yuan Chen, Hua Lan, Yaodong Ping

  • June 17, 2026

Related Content

Alectinib shows promise for the treatment of refractory ALK-positive large B-cell lymphoma: a case report

Correction: MAPRE2 is associated with macrophage-enriched innate immune dysregulation and malignant phenotypes in hepatocellular carcinoma

Pembrolizumab-associated immune-related hepatitis: a retrospective case report analysis